EYPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
EyePoint Inc is not a good buy right now for a Beginner long-term investor, even with $50,000-$100,000 available. The stock has some supportive analyst optimism and promising pipeline catalysts, but the latest quarter shows steep revenue collapse, large losses, and cash burn pressure. With no strong proprietary buy signal, mixed technicals, and currently neutral-to-bearish sentiment, the better call is to hold off rather than buy aggressively now.
EYPT is trading in pre-market at 13.59, near its pivot level of 13.43. The MACD histogram is negative at -0.0367, though contracting, which suggests bearish momentum is easing but not yet reversed. RSI_6 at 43.14 is neutral to slightly weak, and moving averages are converging, pointing to a consolidation phase rather than a strong uptrend. Short-term pattern stats suggest a positive bias, but not a decisive breakout. Key levels are resistance at 14.11 and 14.52, with support at 12.75 and 12.34.
["Citi raised its target to $35 and kept Buy.", "H.C. Wainwright raised its target to $30 and kept Buy after Q4, citing the Phase 3 diabetic macular edema program.", "Chardan raised its target to $29 and kept Buy after Q4 and Duravyu updates.", "Mizuho raised its target to $36 and kept Outperform.", "Q1 update showed low discontinuation rate of about 5% in the wet AMD program.", "More than one-third of patients are already enrolled in the DME pivotal trials, with full enrollment expected by Q3 2026.", "Option flow volume is call-heavy today, suggesting traders are positioning for upside near term."]
["Q1 2026 net revenue fell sharply to $0.7 million from $24.5 million year over year.", "Revenue declined 97.15% year over year in the latest quarter.", "Net income loss widened materially to -$84.8 million.", "Gross margin dropped sharply to 24.14%.", "Cash and investments fell to $223 million, increasing concern about burn rate.", "Analyst estimate revisions have been negative recently, with four downward EPS revisions and none upward in the last three months.", "No recent hedge fund accumulation and insiders are neutral.", "No recent congress trading data or notable political buying support."]
In Q1 2026, EyePoint reported revenue of $696,000, down 97.15% year over year, which is a major deterioration in top-line performance. Net income was -$84.83 million, showing continued heavy losses, and EPS was -0.99. Gross margin fell to 24.14%, also down sharply year over year. The quarter reflects weak current commercialization, ongoing losses, and significant reliance on pipeline execution rather than operating fundamentals.
Analysts remain constructive overall, with multiple target raises in March 2026 and Buy/Outperform ratings from Citi, H.C. Wainwright, Chardan, and Mizuho. Price targets now range roughly from $29 to $36, showing higher long-term expectations. The pros view is that the pipeline, especially Duravyu and DME programs, could create meaningful upside. The cons view is that current revenue is extremely weak, losses are large, and recent estimate revisions have turned cautious. Overall, Wall Street is supportive on the story but not on current fundamentals.
